BIIB122 225 mg
1 treatment and condition followed through the public trial records. Not medical advice. How a status is set
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| BIIB122 225 mg for parkinson disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |